Cargando…

Accuracy of standard clinical 3T prostate MRI for pelvic lymph node staging: Comparison to(68)Ga-PSMA PET-CT

The aim was to assess the performance of prostate 3T MRI for pelvic lymph node (LN) staging in prostate cancer (PCa), in comparison to (68)Gallium-prostate specific membrane antigen PET-CT ((68)Ga-PSMA PET-CT) as reference standard for LN detection. 130 patients with PCa underwent non-contrast-enhan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meißner, Sebastian, Janssen, Jan-Carlo, Prasad, Vikas, Diederichs, Gerd, Hamm, Bernd, Brenner, Winfried, Makowski, Marcus R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656738/ https://www.ncbi.nlm.nih.gov/pubmed/31341209 http://dx.doi.org/10.1038/s41598-019-46386-3

Ejemplares similares

Potential of asphericity as a novel diagnostic parameter in the evaluation of patients with (68)Ga-PSMA-HBED-CC PET-positive prostate cancer lesions
por: Meißner, Sebastian, et al.
Publicado: (2017)

(68)Ga-PSMA-PET/CT for the evaluation of liver metastases in patients with prostate cancer
por: Damjanovic, Jonathan, et al.
Publicado: (2019)

Lesion-to-background ratio threshold value of SUVmax of simultaneous [(68)Ga]Ga-PSMA-11 PET/MRI imaging in patients with prostate cancer
por: Zhao, Jing, et al.
Publicado: (2020)

(68)Ga-PSMA-PET/CT for the evaluation of pulmonary metastases and opacities in patients with prostate cancer
por: Damjanovic, Jonathan, et al.
Publicado: (2018)

Dynamic Contrast-Enhanced MRI of Prostate Lesions of Simultaneous [(68)Ga]Ga-PSMA-11 PET/MRI: Comparison between Intraprostatic Lesions and Correlation between Perfusion Parameters
por: Zhao, Jing, et al.
Publicado: (2021)

Correlation between Intraprostatic PSMA Uptake and MRI PI-RADS of [(68)Ga]Ga-PSMA-11 PET/MRI in Patients with Prostate Cancer: Comparison of PI-RADS Version 2.0 and PI-RADS Version 2.1
por: Zhao, Jing, et al.
Publicado: (2020)

Cribriform pattern disease over‐represented in pelvic lymph node metastases identified on (68)GA PSMA‐PET/CT
por: Bolton, Damien, et al.
Publicado: (2022)

In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2(nd) Cycle Is Better Predictor of Overall Survival of Prostate Cancer Patients Treated With (177)Lu-PSMA
por: Prasad, Vikas, et al.
Publicado: (2021)

Accuracy of (68)Ga-PSMA PET-CT and PET-MRI in lymph node staging for localized prostate cancer
por: Barbosa, Álan Roger Gomes, et al.
Publicado: (2022)

PSMA Expression in Multinodular Thyroid Neoplasm on Simultaneous Ga-68-PSMA PET/MRI
por: Jena, Amarnath, et al.
Publicado: (2017)

[(68)Ga]Ga-PSMA PET/MRI, histological PSMA expression and preliminary experience with [(177)Lu]Lu-PSMA therapy in relapsing high-grade glioma
por: Truckenmueller, Peter, et al.
Publicado: (2022)

Mesorectal Lymph Node Metastases as Index Lesion in (68)Ga-PSMA-PET/CT Imaging for Recurrent Prostate Cancer
por: Leitsmann, Conrad, et al.
Publicado: (2021)

Musculoskeletal pitfalls in (68)Ga-PSMA PET/CT
por: Pontes, Írline Cordeiro de Macedo, et al.
Publicado: (2023)

(68)Ga-PSMA ligand PET/CT integrating indocyanine green-guided salvage lymph node dissection for lymph node metastasis after radical prostatectomy
por: Li, Teng-Cheng, et al.
Publicado: (2021)

Prospective evaluation of the performance of [(68)Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy
por: Abufaraj, Mohammad, et al.
Publicado: (2019)

Pelvic salvage (SBRT) radiotherapy based on (68)Ga-PSMA PET/CT: About a case
por: Slaoui, A., et al.
Publicado: (2019)

Research Highlight: (68)Ga-PSMA-11 PET Imaging for Pelvic Nodal Metastasis in Prostate Cancer
por: Fütterer, Jurgen J., et al.
Publicado: (2022)

PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and (68)Ga‐PSMA‐11 PET Using Cyclotron‐Produced (68)Ga
por: Thompson, Scott M., et al.
Publicado: (2021)

[(68)Ga]Ga-PSMA-11: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
por: Hennrich, Ute, et al.
Publicado: (2021)

Multiparametric dynamic whole-body PSMA PET/CT using [(68)Ga]Ga-PSMA-11 and [(18)F]PSMA-1007
por: Dias, André H., et al.
Publicado: (2023)

Salvage lymph node dissection after (68)Ga-PSMA or (18)F-FEC PET/CT for nodal recurrence in prostate cancer patients
por: Herlemann, Annika, et al.
Publicado: (2017)

Diagnostic Accuracy of Ga-68-HBED-CC-PSMA-Ligand-PET/CT before Salvage Lymph Node Dissection for Recurrent Prostate Cancer
por: Jilg, Cordula A., et al.
Publicado: (2017)

Use of (68)Ga-PSMA-11 and (18)F-FDG PET-CT Dual-Tracer to Differentiate Between Lymph Node Metastases and Ganglia
por: Shi, Yiping, et al.
Publicado: (2021)

Investigation of the halo-artifact in (68)Ga-PSMA-11-PET/MRI
por: Heußer, Thorsten, et al.
Publicado: (2017)

Comparison of [(18)F]DCFPyL and [(68)Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer
por: Dietlein, Markus, et al.
Publicado: (2015)

Comparison of (68)Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer
por: Zhang, Qing, et al.
Publicado: (2017)

Prostate Cancer Nodal Staging: Using Deep Learning to Predict (68)Ga-PSMA-Positivity from CT Imaging Alone
por: Hartenstein, A., et al.
Publicado: (2020)

(68)Ga-PSMA-11 PET/CT versus (68)Ga-PSMA-11 PET/MRI for the detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis
por: Huang, Ruizhe, et al.
Publicado: (2023)

Primary Staging of Prostate Cancer Patients with [(18)F]PSMA-1007 PET/CT Compared with [(68)Ga]Ga-PSMA-11 PET/CT
por: Hoffmann, Manuela A., et al.
Publicado: (2022)

Voxel-based comparison of [(68)Ga]Ga-RM2-PET/CT and [(68)Ga]Ga-PSMA-11-PET/CT with histopathology for diagnosis of primary prostate cancer
por: Fassbender, Thomas Franz, et al.
Publicado: (2020)

(68)Ga-PSMA PET-CT Imaging of Metastatic Adenoid Cystic Carcinoma
por: de Keizer, Bart, et al.
Publicado: (2016)

(68)Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients
por: Sathekge, Mike, et al.
Publicado: (2016)

Specificity of (68)Ga-PSMA PET/CT for Prostate Cancer - Myths and Reality
por: Sasikumar, Arun
Publicado: (2017)

Letter to the Editor: (68)Ga-PSMA-11 for renal cortical PET imaging
por: Sarikaya, Ismet
Publicado: (2022)

Development and external validation of a multivariable [(68)Ga]Ga-PSMA-11 PET-based prediction model for lymph node involvement in men with intermediate or high-risk prostate cancer
por: Muehlematter, Urs J., et al.
Publicado: (2023)

High negative predictive value of 68Ga PSMA PET-CT for local lymph node metastases in high risk primary prostate cancer with histopathological correlation
por: Rahman, Labib Ataur, et al.
Publicado: (2019)

The Establishment of New Thresholds for PLND-Validated Clinical Nomograms to Predict Non-Regional Lymph Node Metastases: Using (68)Ga-PSMA PET/CT as References
por: Jiao, Jianhua, et al.
Publicado: (2021)

PSMA-Positive Follicular Thyroid Carcinoma Incidentally Detected by [(68)Ga]Ga-PSMA-11 PET/CT: Correlation with Immunohistology Confirms Neovascular PSMA-Expression
por: Rosar, Florian, et al.
Publicado: (2022)

Detection of neuroendocrine tumours in the small intestines using contrast-enhanced multiphase Ga-68 DOTATOC PET/CT: the potential role of arterial hyperperfusion
por: Schreiter, Nils F., et al.
Publicado: (2014)

(44)Sc-PSMA-617 for radiotheragnostics in tandem with (177)Lu-PSMA-617—preclinical investigations in comparison with (68)Ga-PSMA-11 and (68)Ga-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ab3avvhfksfs7tnkphjaag8lb6